CORT
Undervalued by 194.9% based on the discounted cash flow analysis.
Market cap | $2.35 Billion |
---|---|
Enterprise Value | $1.98 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.95 |
Beta | 1.01 |
Outstanding Shares | 103,520,000 |
Avg 30 Day Volume | 768,857 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 22.1 |
---|---|
PEG | 24.87 |
Price to Sales | 5.55 |
Price to Book Ratio | 5.55 |
Enterprise Value to Revenue | 4.1 |
Enterprise Value to EBIT | 18.43 |
Enterprise Value to Net Income | 18 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...